Eric Easom - Feb 26, 2025 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role: Chief Executive Officer, Director
Signature: /s/ Lucy Day, Attorney-in-Fact for Eric Easom
Stock symbol: ANTX
Transactions as of: Feb 26, 2025
Transactions value $: $0
Form type: 4
Date filed: 2/28/2025, 04:22 PM
Previous filing: Nov 18, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANTX	Common Stock	Award	$0	+145K	+143.63%	$0.00	246K	Feb 26, 2025	Direct	F1, F2
holding	ANTX	Common Stock						1.07M	Feb 26, 2025	See Footnote	F3
holding	ANTX	Common Stock						97.1K	Feb 26, 2025	See Footnote	F4
holding	ANTX	Common Stock						97.1K	Feb 26, 2025	See Footnote	F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANTX	Stock Option (right to buy)	Award	$0	+291K		$0.00	291K	Feb 26, 2025	Common Stock	291K	$1.13	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.
F2	Includes a balance of 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of each such date.
F3	Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
F4	Consists of shares of Common Stock held by the C. Easom Irrevocable Trust dated October 8, 2021.
F5	Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.
F6	The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.